Imaging Tumors That Carry the CAIX Protein With a PET Scan
Tests a PET scan tracer that finds CAIX-carrying solid tumors in adults.
Plain-language title generated from the registry record
Registry title: 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with confirmed or suspected solid tumors, such as kidney, bladder, bowel, lung or liver cancer, to test a new PET/CT scan probe called 18F-T2.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Confirmed or suspected tumors of types such as clear cell renal cell cancer, urothelial carcinoma, colorectal cancer, cervical cancer, ovarian cancer, head and neck cancer, hepatocellular carcinoma, cholangiocarcinoma, non small cell lung cancer, small cell lung cancer, breast cancer, pancreatic cancer, endometrial cancer, or Von Hippel Lindau Disease. The list is not limited to these.
Main reasons for not taking part
- A serious non-malignant illness (for example psychiatric, infectious, autoimmune or metabolic) that could interfere with the trial or safety, as judged by the investigator
- A mental impairment that could stop you from giving informed consent or following the trial rules
- Being pregnant or breastfeeding
Read by machine on 12 November 2026.
Where in China
- Peking University First HospitalBeijing, ChinaContact: Peking University First HospitalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University First Hospital
- Trial code
- NCT07557225
- Record updated
- 14 May 2026
- Original description
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors. It will also assess the safety, tolerability and radiation dosimetry of 18F-T2.Read full original descriptionShow less
Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for Tumors Likely to Express High Levels of CAIX
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors. It will also assess the safety, tolerability and radiation dosimetry of 18F-T2.
Inclusion: All participants must meet the following criteria:; Written and voluntarily given Informed Consent; Male or female ≥18 years of age at time of consent; Have the capacity to understand the study and be willing and able to comply with all protocol requirements; Participants with histologically confirmed or suspected tumors of the following types, but not limited to:; Clear Cell Renal Cell Cancer; Urothelial Carcinoma; Colorectal Cancer; Cervical Cancer; Ovarian Cancer; Head and Neck Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Non Small Cell Lung Cancer; Small Cell Lung Cancer; Breast Cancer; Pancreatic Cancer; Endometrial Cancer; Von Hippel Lindau Disease.
Exclusion: Have any serious non-malignant disease (e.g., psychiatric, infectious, autoimmune or metabolic) that may interfere with the objectives of the study or with the safety or compliance of the participant, as judged by the Investigator; Have a mental impairment that may compromise the ability to give Informed Consent and comply with the requirements of the study; Participants will be excluded from participation in the study if one or more of the following criteria are met:; Be a female who is pregnant or breastfeeding.